Our study demonstrates that Intranasal Corticosteroid (INCS) usage is associated with decreased COVID-19-related hospital admission, ICU admission, and mortality. Our findings demonstrate the need for future studies including Randomized Controlled Trials (RCTs) on INCS usage to corroborate our findings and determine whether INCS improves health care-related outcomes due to COVID-19.

Dr. Strauss and The Cleveland Allergy and Asthma Center completed this study in parternship with researchers at:

• Respiratory Institute, Cleveland Clinic

• Lerner Research Institute, Cleveland Clinic

• Division of Pulmonary and Critical Care Medicine, Department of Medicine, Wake Forest School of Medicine.

This paper was published in the Journal of Allergy, Asthma & Immunology: In Practice.

The full article is provided here in PDF format.